tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000031791 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
MRNACRLVEEVPODDWSTRVTY
NYSE Health care · Lab Instruments

Revvity RVTY

RVTY quote by TradingView

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. 10-K, Item 1

Employees
11,000
Headquarters
Waltham, MA
CEO
Prahlad R. Singh
Next results
around Jan 12, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2022

Revenue of $3.3B through the costs to a net profit of $569.2M · income statement of the 10-K

22% operating margin
Revenue to Gross profit: $2.0BRevenue to Cost of revenue: $1.3BGross profit to Operating profit: $742.7MGross profit to Operating expenses: $1.2BOperating profit to Net profit: $569.2MOperating profit to Tax & other: $173.5MOperating expenses to R&D: $221.6MOperating expenses to SG&A: $1.0B Revenue: $3.3B REVENUE $3.3B −13% Y/Y Gross profit: $2.0B · 60% margin GROSS PROFIT $2.0B 60% margin · −18% Y/Y Cost of revenue: $1.3B · 40% of revenue COST OF REVENUE $1.3B 40% of revenue Operating profit: $742.7M · 22% margin OPERATING PROFIT $742.7M 22% margin · −41% Y/Y Operating expenses: $1.2B · 38% of revenue OPERATING EXPENSES $1.2B 38% of revenue Net profit: $569.2M · 17% margin NET PROFIT $569.2M 17% margin · −40% Y/Y Tax & other: $173.5M · 5% of revenue TAX & OTHER $173.5M 5% of revenue R&D: $221.6M · 7% of revenue R&D $221.6M 7% of revenue SG&A: $1.0B · 31% of revenue SG&A $1.0B 31% of revenue
Gross profit $2.0B 60% margin · −18% Y/Y
Operating profit $742.7M 22% margin · −41% Y/Y
Net profit $569.2M 17% margin · −40% Y/Y
The full income statement, year by year

RVTY among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 3.7%, above 25% of 59 peers (their median 7.2%) REVENUE GROWTH 3.7% · above 25% Operating margin: 12.6%, above 42% of 50 peers (their median 13.7%) OPERATING MARGIN 12.6% · above 42% Net margin: 8.6%, above 44% of 59 peers (their median 9.7%) NET MARGIN 8.6% · above 44% FCF margin: 20.1%, above 67% of 55 peers (their median 15.2%) FCF MARGIN 20.1% · above 67% Return on capital: 3.2%, above 2% of 41 peers (their median 9.2%) RETURN ON CAPITAL 3.2% · above 2%
RVTY Peer median Below the median

What changed

4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 24, 2026 against Feb 25, 2025.

Risk factors
4 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Receivables growing faster than revenue
Receivables +17.8% vs revenue +3.7% (+14.1 pts)
10-K · XBRL
Accounting checks
10 other checks clear, 1 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
3 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +17.8% vs revenue +3.7% (+14.1 pts)
  • Cash from operations $582.9M vs net income $241.2M (FY ending Dec 28, 2025)
9 more checks with nothing to note
  • Inventory +3.2% vs revenue +3.7% (-0.4 pts)
  • Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Goodwill - Life Sciences Solutions Reporting Unit; Boston, Massachusetts; February 24, 2026
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

4 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 4 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation. We are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business. The…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    We cannot predict the scope, timing, or impact of threatened U.S. tariffs on imports, the extent to which other countries may impose retaliatory trade restrictions, or the terms of future trade policy changes. Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$3.3B$2.8B$2.8B$2.9B
Net income$569.2M$693.1M$270.4M$241.2M
Operating cash flow$679.8M$91.3M$628.3M$582.9M
Free cash flow$594.2M$9.9M$541.7M$509.4M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.9B ▲ 3.7% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Revvity, Waltham, MA · from the 10-K filed Feb 24, 2026

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees.

Headquarters
Waltham, MA
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 29
Last results
Nov 3, 2026
Incorporated in
MA

Employees, at the top of the page: "As of December 28, 2025, we employed approximately 11,000 employees" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RVTY/export.csv") into a cell.